Aktis Oncology, Inc.
NASDAQ:AKTSBiotechnology
+$0.11 today
- Market cap
- $865.32M
- Beta
- 1.10
- P/E (TTM)
- -28.7
- EPS (TTM)
- -$0.82
Volume 0.44M
Average 0.33M
AKTS Short-term Investments
Marketable securities and deposits the company expects to convert to cash within a year.
Aktis Oncology, Inc.NASDAQ: AKTS
Short-term Investments · Q1 FY2026 · quarter ended Mar 2026
Short-term investments of $166.85M in Q1 FY2026
Q1 FY2026 short-term investments was $166.85M.
Context
- Short-term investments amounted to 28.9% of total assets at the end of Q1 FY2026.
- Short-term investments increased in 2 of the last 3 fiscal years.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Investments history
USD · from the balance sheet
- Latest · FY2025
- 189M USD
- Year-over-year change
- -27.3%
| Period | Period end | Short-term Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 189M | -27.3% |
| FY2024 | 2024-12-31 | 260.01M | +280.4% |
| FY2023 | 2023-12-31 | 68.35M | — |
| FY2022 | 2022-12-31 | 0 | — |
Short-term Investments vs competitors
How AKTS compares with its peers on the latest reported figures
- AKTS's Mar 2026 short-term investments of $166.85M is the 3rd highest of the 6 companies compared; the peer median is $87.71M.
- Short-term investments amounts to 28.9% of total assets for AKTS, versus a peer median of 36.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $392.22M | +8.9% | — | 36.6% | |
| Sep 2026 | $248.74M | — | — | 49.2% | |
| Mar 2026 | $166.85M | — | — | 28.9% | |
| Mar 2026 | $87.71M | +923.4% | +42.9% | 40.3% | |
| Mar 2026 | $29.94M | -66.6% | +8.0% | 21.7% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding AKTS) | $87.71M | +8.9% | +25.5% | 36.6% | |
Competitors are the stored peer set for AKTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Aktis Oncology, Inc.
NASDAQ:AKTS
Intrinsic Alpha fair value
Locked
Current Price
$16.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.